Board renewal at Spanish generics associationThe Spanish association of generics manufacturers (AESEG) has renewed its board and changed its structure, financial El Economista and medical journal Redacción Médica report on Friday.
Positive Phase III for Celgene in Behçet’s diseaseCelgene’s psoriasis drug Otezla (apremilast) is effective to treat oral ulcers in Behçet disease according to the results of the Relief study, presented at the annual meeting of the American Academy of Dermatology, Europa Press agency, financial El Economista, medical journals Gaceta Médica, Redacción Médica and Diario Médico reported on Thursday. (APMHE 56950)
New tool to predict breast cancer response to chemoResearchers from Columbia University in New York have developed a diagnostic test based on near-infrared light to identify how breast cancer patients will respond to chemotherapy in just two weeks, daily ABC and IM Médico Hospitalario reported on Wednesday.
Shire warns of 'limited growth'Shire’s sales grew more than expected - by 33% - in 2017, mainly driven by the acquisition of Baxalta. However, growth in diluted earnings per share will be below sales growth due to the cost of its new plant in the U.S. and increased generic competition, financial El Economista reported on Tuesday. (APMHE 56880)
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.